The International Consortium for Personalised Medicine (ICPerMed) has published a new White Paper on “the Value and Evaluation of Personalised Medicine”.
Over a period of three years, the ICPerMed Health Economic Working Group has led a workshop and other activities to explore the health economic aspects of Personalised Medicine approaches. The objective of this White Paper is to reflect on the particularities of these aspects compared to “traditional” approaches to facilitate an active dialogue between researchers, innovators, funders and decision-makers. By doing so, we can continue to explore how to define new models to integrate evidence to estimate the short-term and longer-term downstream consequences of personalised medicine. This undertaking is especially complex for personalised medicine, as the downstream consequences and spillover effects of personalised medicine impact society at large.
EP PerMed is collaborating closely with ICPerMed and its Working Groups to support the ICPerMed initiative. EP PerMed Coordinator Wolfgang Ballensiefen and Kathleen D’Hondt (lead of EP PerMed Work Package 3) have coauthored the ICPerMed White Paper.